BroadOak Expands Life Sciences Investment Platform with $200M Commitment
BroadOak Capital Partners, a life science–focused investment and advisory firm, has secured over $200 million in new capital commitments from BroadOak principals and longtime strategic partner Research Corporation Technologies (RCT). The additional funding expands the firm’s investing capacity across its growth equity and private credit strategies, enabling it to deploy more capital into innovative companies advancing the life sciences ecosystem.
The new commitments will be used primarily to invest alongside BroadOak’s existing and future funds, deepening alignment with portfolio companies and limited partners.
“While we all manage through the current headwinds in the private capital markets, BroadOak can now lean into what we believe is an excellent environment for life sciences investors while also assuring our broader stakeholders of our longevity,” said Bill Snider, Partner at BroadOak.
Earlier this year, BroadOak achieved several key milestones, including the final close of the BroadOak Income Fund in March 2025. The fund is a private credit vehicle designed to provide flexible financing to mature, credit-constrained life sciences companies.
The firm also held the initial close of Fund VI in June 2025, continuing its flagship growth capital fund series, focused on tools, diagnostics, and biopharma services that underpin healthcare infrastructure.
“The industry has been hampered by lower volumes of financings and M&A transactions, but scientific progress hasn’t stopped,” Snider added. “The best vintage years often emerge from the toughest markets.”
Since inception, BroadOak has invested in more than 75 companies across multiple funds and vehicles and advised on over 50 M&A transactions.
